Overview
High blood pressure is not, on its own, a reason you cannot have hormone therapy. What it does is change two things: which route is appropriate, and what has to happen first.
The short version: blood pressure should be controlled before starting, transdermal delivery is generally preferred over oral, and it should be monitored on treatment rather than assumed.
| What applies | |
|---|---|
| Controlled hypertension on treatment | Generally not a barrier. Transdermal usually preferred |
| Uncontrolled hypertension | Address it first. Not a permanent exclusion — a sequencing issue |
| Oral estrogen | Passes through the liver; can raise blood pressure in some women |
| Transdermal estradiol | Generally preferred where blood pressure is a concern |
| Vaginal estrogen | Minimal systemic absorption. Blood pressure is not the same consideration |
| Monitoring | Baseline, then checked on treatment — not assumed |
The context worth having: blood pressure rises through the menopause transition for reasons that are partly independent of treatment, and it is the most under-monitored cardiovascular risk factor in midlife women. A lot of women discover a raised reading at a hormone therapy consultation, and finding it is the useful part.
Why the route matters here
The same first-pass mechanism that governs clot risk is relevant to blood pressure.
Oral estrogen is absorbed from the gut into the portal vein and passes through the liver at high concentration before reaching the rest of the body. The liver responds by changing what it produces — including angiotensinogen, a precursor in the renin-angiotensin system that regulates blood pressure. In some women that contributes to a rise.
Transdermal estradiol — a patch, gel or spray — is absorbed through skin into the general circulation, so the liver sees it at ordinary concentrations. The hepatic effects are largely absent, and transdermal delivery is generally regarded as blood-pressure neutral.
Which is why, for a woman with hypertension, the route is the main lever and not the decision about whether to treat at all. How the two routes differ across the board.
The progestogen matters too. Progestogens differ from one another considerably, and some have antimineralocorticoid activity that can be modestly favorable for fluid retention and blood pressure. Which one is appropriate is part of the same conversation. Progestin and progesterone are not the same thing.
"Controlled" is the operative word
The distinction that determines the answer is not whether you have hypertension. It is whether it is controlled.
Controlled hypertension — on treatment, with readings at target — is generally not a barrier to hormone therapy for a woman who otherwise has an indication for it.
Uncontrolled hypertension is a reason to address that first. This is sequencing rather than exclusion: it is not that you cannot have hormone therapy, it is that the blood pressure gets sorted out and then the conversation continues.
That ordering matters for a reason beyond hormone therapy. Uncontrolled hypertension is a leading contributor to stroke and heart disease, and it is worth treating in its own right regardless of what else you are considering.
What should happen before and during
Before starting:
- Blood pressure measured properly — more than one reading, correct cuff size, seated and rested. A single high reading in a clinic is not a diagnosis
- A full cardiovascular risk assessment: lipids including ApoB, glucose and HbA1c, weight, smoking, family history. Why ApoB is more informative than standard cholesterol
- A clot risk assessment, since the factors overlap — previous clot, thrombophilia, migraine with aura, weight
- Treatment of the blood pressure where it is not at target
On treatment:
- Blood pressure checked at follow-up rather than assumed
- Home monitoring, which is more informative than occasional clinic readings and picks up what a single appointment misses
- A review if readings rise after starting — which may mean a route change rather than stopping
Migraine with aura, which comes up alongside this
Worth naming because it frequently travels with the blood pressure conversation and is often misunderstood.
Migraine with aura is associated with increased stroke risk, and that risk is relevant to how estrogen is delivered.
The important distinction: the concern with combined hormonal contraception in migraine with aura relates to the higher-dose synthetic ethinylestradiol used in contraception. Menopausal hormone therapy uses lower amounts of estradiol, and current guidance generally regards transdermal menopausal hormone therapy as appropriate for women with migraine with aura.
That is a genuine and consequential difference, and women are frequently told they cannot have hormone therapy on the basis of contraception guidance that does not apply to it. It is worth raising specifically.
Vaginal estrogen is a different question
Low-dose vaginal estrogen has minimal systemic absorption, so the blood pressure considerations above do not apply to it in the same way.
For a woman whose blood pressure rules out or delays systemic treatment, local treatment for vaginal dryness, discomfort with sex and urinary symptoms remains available — and those symptoms are progressive without treatment, so it is worth pursuing rather than waiting. What local treatment does.
Frequently asked questions
Can I take HRT with high blood pressure? Generally yes if it is controlled, with transdermal delivery usually preferred. Uncontrolled hypertension should be addressed first — that is sequencing rather than a permanent exclusion.
Does HRT raise blood pressure? Oral estrogen can contribute to a rise in some women through its hepatic effects. Transdermal estradiol is generally regarded as blood-pressure neutral.
Which route should I use? Where blood pressure is a concern, transdermal is generally preferred, because it avoids the first-pass hepatic effects that oral delivery produces.
I have migraine with aura — am I excluded? Frequently women are told so on the basis of contraceptive guidance, which uses a different and higher-dose estrogen. Current guidance generally regards transdermal menopausal hormone therapy as appropriate. Worth raising specifically.
What about vaginal estrogen? Minimal systemic absorption means the blood pressure considerations do not apply in the same way, and it remains available for local symptoms.
Where this fits in your plan
The productive way to approach this is not "am I allowed" but "what needs to be true first, and which route suits me."
That means a proper blood pressure measurement, a full cardiovascular risk picture, and a route chosen for your situation rather than by default. What we check, and what hormone therapy with us involves.
We measure first. Then we act.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
